Navigation Links
Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction
Date:10/27/2010

TEMPE, Ariz., Oct. 27 /PRNewswire/ -- Intrinsic Bioprobes today announced that the United States Patents and Trademark Office has issued US Patent 7,816,095 covering novel blood protein biomarkers related to cardiovascular disease. This patent is first of a series of patent applications that cover specific human protein variants as biomarkers with clinical utility.

"The biomarkers were discovered using Intrinsic Bioprobes' unique Mass Spectrometric Immunoassay technologies," says Urban Kiernan, Ph.D., the Director of Biomarker Discovery at Intrinsic Bioprobes. These newly identified biomarkers are modified forms of specific circulating blood proteins that, when used in combination, yield exceptional clinical sensitivity and specificity in the determination of myocardial infarction. "We are very excited about these biomarkers because they clearly demonstrate the significance of protein microheterogeneity in human disease, which has been largely unexplored niche in human molecular biology," adds Kiernan.

Intrinsic Bioprobes Inc. (IBI), located in Tempe, AZ, performs unbiased discovery, verification and population studies on full-length proteins, and discovers and defines microheterogeneity in disease-associated biomarker proteins within healthy and disease populations. IBI's principal focus is the development and application of clinical and diagnostic assays and platforms for rapid and sensitive protein biomarker analysis for early detection and efficient treatment of critical human diseases. IBI's advanced technologies are patented and proprietary process platforms and approaches for proteomic and other research and clinical applications that generally leverage advanced mass spectrometry technology. These approaches include IBI's MASSAY(R) technology system, its Mass Spectrometric Immunoassay (MSIA(TM)) technology and its Bioreactive Probes (BRP(TM)). The Company has developed a deep and growing base of intellectual property in its field, consisting of 19 issued patents and numerous pending patent applications.

For more information about Intrinsic Bioprobes Inc., please visit http://www.intrinsicbio.com.Contact: Dobrin NedelkovIntrinsic Bioprobes Inc.Tel. (480) 804-1778E-mail: info@intrinsicbio.comThis press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Intrinsic Bioprobes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
2. Onyx Pharmaceuticals Announces Third Quarter 2010 Financial Results Teleconference and Webcast
3. Baxa Corporation Announces 2011 Course Schedule for its STAR Center® Training Facility
4. Baltimores Mark E. Spier, DPM, Announces FDA Clearance of PinPointe™ FootLaser™ for Treatment of Nail Fungus
5. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
6. Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call
7. Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010
8. NCPA Announces Partnership with Live Oak Bank to Help Finance Independent Community Pharmacy Purchases
9. Trius Announces Issuance of Key U.S. Patent for Torezolid Phosphate
10. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
11. Roper Industries Announces Record Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  The University of Michigan ... announced today that, as part of the development of ... the first hospitals in the U.S. to start using ... , M.D., U-M,s chair of neurosurgery. --> ... --> The BrightMatter technology from Synaptive ...
(Date:2/8/2016)... -- Avista Pharma Solutions ("Avista Pharma") announced today that it ... (CFO). Mr. Setzer is a finance and operations executive ... within growing technology and life science companies. Prior to ... of Finance at INC Research, a publicly traded clinical ... Previously, Mr. Setzer served as CFO of Expression Analysis, ...
(Date:2/8/2016)... -- Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) today announced that ... 31, 2015, the Company achieved revenue of $8,195,839, a 27% ... in fiscal 2015. --> --> ... 2016 was $2,068,635, or $.03 per share, up 265% from ... the Q2 of fiscal year 2015. Gross margin for the ...
Breaking Medicine Technology:
(Date:2/8/2016)... Pekin, IL (PRWEB) , ... February 08, 2016 ... ... debilitating conditions that co-occur frequently. While a significant number of women and men ... PTSD, not the trauma itself, that best predicts the development of an eating ...
(Date:2/8/2016)... , ... February 08, 2016 , ... TopConsumerReviews.com recently awarded ... Mole removal products. , Moles are derived from a cluster of melanin when exposed ... the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February ... ... to correct pelvic organ prolapse with the latest techniques and the most minimally ... risk for pelvic organ prolapse, particularly after menopause. Other risk factors include surgery ...
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is proud ... . This event brings together top non-profit leaders, ultimate organizations, and coaches from around ... Valerio Iani, Bay Area Disc Program Director of Youth and Education, describes this year ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
Breaking Medicine News(10 mins):